Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase

Lancet. 2000 Feb 19;355(9204):626-7. doi: 10.1016/s0140-6736(99)04215-4.

Abstract

The use of donor T cells expressing a suicide gene for destruction of graft-versus-host effector cells provides a tool for alloreactivity modulation. We describe a case of extensive vitiligo that developed after ganciclovir treatment of cutaneous chronic graft-versus-host disease in a patient who had received donor T lymphocytes expressing herpes simplex virus thymidine kinase at the time of transplantation.

Publication types

  • Case Reports
  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Bone Marrow Transplantation
  • Ganciclovir / adverse effects*
  • Ganciclovir / therapeutic use
  • Graft vs Host Disease / drug therapy*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Male
  • Simplexvirus / enzymology*
  • T-Lymphocytes / transplantation*
  • Thymidine Kinase / metabolism*
  • Vitiligo / chemically induced*

Substances

  • Antiviral Agents
  • Thymidine Kinase
  • Ganciclovir